Answers are grounded in this paper and cite their sources.
Retrospective study finds adjuvant somatostatin analogues do not reduce repeated resections in gastric type 1 NENs, suggesting alternative approaches may be needed.
Background: Gastric type 1 neuroendocrine neoplasms (gNENs) are relatively indolent malignancies with low metastatic potential. Endoscopic resection (ER) is considered the primary treatment, while somatostatin analogs (SSAs) have proven anti-secretory and anti-proliferative effects. However, routine adjuvant SSA therapy after ER is not universally recommended. Objective: To determine whether adjuvant therapy with SSAs in patients with type 1 gNENs affects the rate of repeated endoscopic resections due to metachronous lesions. Methods: We conducted a retrospective, single-center study which included patients with gNENs cT1–2N0M0, Grade I–II who underwent ER from 2007 to 2024. Two groups were compared: one received SSAs in the adjuvant setting, the other remained under observation only. Propensity score matching using a “cardinality matching” approach ensured balanced cohorts. The primary endpoint was the frequency of repeated ER. Statistical analyses were performed using Student’s t-test. Results: After matching, there was no statistically significant reduction in repeated ER among patients receiving SSAs (p > 0.05). Furthermore, no significant difference in the number of endoscopic examinations was observed between the groups. Conclusion: Routine adjuvant SSA therapy after ER does not appear to reduce the frequency of repeated resections in patients with type 1 gastric NENs, suggesting that such practice may be unnecessary.
No takes yet. Share an insight, caveat, or question.
Peregorodiev et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: